Up- and Down-regulation of Adiponectin Expression and Multimerization: Mechanisms and Therapeutic Implication

Overview

Journal Biochimie

Specialty Biochemistry

Date 2012 Feb 21

PMID 22342903

Citations 20

Authors

Meilian Liu

Feng Liu

Affiliations

Soon will be listed here.

Abstract

Adiponectin has been receiving a great deal of attention due to its potential therapeutic use for metabolic and cardiovascular disorders. Adiponectin expression levels and multimerization are down-regulated in obesity and up-regulated by insulin sensitizers such as thiazolidinediones (TZDs), metformin, sulfonylurea and resveratrol (RSV). The precise mechanisms underlying adiponectin up- and down-regulation remain largely unknown, but recent studies indicate that the cellular and plasma levels of adiponectin could be regulated at both transcriptional and post-transcriptional levels. At the post-translational level, TZDs and resveratrol promote adiponectin levels and multimerization via up-regulation of disulfide-bond-A oxidoreductase-like protein (DsbA-L). Adiponectin levels are also stimulated by FOXO1 and AMP-activated protein kinase (AMPK), and are suppressed by PKA or silencing mediator of retinoid and thyroid hormone receptors (SMRT). Since multimerization is important not only for adiponectin function but also for stability, increasing adiponectin multimerization has become a promising drug target for the treatment of metabolic diseases and other related disorders.

Citing Articles

The Effect of Isotretinoin on Insulin Resistance and Serum Adiponectin Levels in Acne Vulgaris Patients: A Systematic Review and Meta-Analysis.

Paschalidou E, Katsaras G, Papoulakis T, Kalloniati E, Kavvadas D, Karachrysafi S Clin Pract. 2024; 14(3):1021-1037.

PMID: 38921259 PMC: 11202953. DOI: 10.3390/clinpract14030081.

New insights of DsbA-L in the pathogenesis of metabolic diseases.

Li S, Wan J, Peng Z, Huang Q, He B Mol Cell Biochem. 2024; 479(12):3293-3303.

PMID: 38430301 DOI: 10.1007/s11010-024-04964-8.

DsbA-L: A Promising Therapeutic Target for Metabolic Diseases.

Yang M, Luo S, Yang J, Chen W, He L, Liu D Curr Med Chem. 2023; 32(5):982-991.

PMID: 37877503 DOI: 10.2174/0109298673252630231018044159.

Circulating adiponectin levels, expression of adiponectin receptors, and methylation of adiponectin gene promoter in relation to Alzheimer's disease.

Kaiyrlykyzy A, Umbayev B, Masoud A, Baibulatova A, Tsoy A, Olzhayev F BMC Med Genomics. 2022; 15(1):262.

PMID: 36527105 PMC: 9756783. DOI: 10.1186/s12920-022-01420-8.

An Explanation for the Adiponectin Paradox.

Kalkman H Pharmaceuticals (Basel). 2021; 14(12).

PMID: 34959666 PMC: 8703455. DOI: 10.3390/ph14121266.

References

Reilly S, Bhargava P, Liu S, Gangl M, Gorgun C, Nofsinger R . Nuclear receptor corepressor SMRT regulates mitochondrial oxidative metabolism and mediates aging-related metabolic deterioration. Cell Metab. 2010; 12(6):643-53. PMC: 3033658. DOI: 10.1016/j.cmet.2010.11.007. View

Cascon A, Ruiz-Llorente S, Cebrian A, Telleria D, Rivero J, Diez J . Identification of novel SDHD mutations in patients with phaeochromocytoma and/or paraganglioma. Eur J Hum Genet. 2002; 10(8):457-61. DOI: 10.1038/sj.ejhg.5200829. View

Tsunekawa T, Hayashi T, Suzuki Y, Matsui-Hirai H, Kano H, Fukatsu A . Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care. 2003; 26(2):285-9. DOI: 10.2337/diacare.26.2.285. View

Fujita H, Fujishima H, Koshimura J, Hosoba M, Yoshioka N, Shimotomai T . Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice. Endocr J. 2005; 52(4):427-33. DOI: 10.1507/endocrj.52.427. View

Kim Y, Park K, Lee Y, Park Y, Kim D, Nedumaran B . Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes. 2007; 57(2):306-14. DOI: 10.2337/db07-0381. View

Park S, Shin H, Lee J, Kim C, Lee W, Rhim B . Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription. J Pharmacol Exp Ther. 2009; 329(2):571-9. DOI: 10.1124/jpet.108.146456. View

Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K . cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996; 221(2):286-9. DOI: 10.1006/bbrc.1996.0587. View

Wang A, Liu M, Liu X, Dong L, Glickman R, Slaga T . Up-regulation of adiponectin by resveratrol: the essential roles of the Akt/FOXO1 and AMP-activated protein kinase signaling pathways and DsbA-L. J Biol Chem. 2010; 286(1):60-6. PMC: 3013020. DOI: 10.1074/jbc.M110.188144. View

Hsi L, Wilson L, Nixon J, Eling T . 15-lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor gamma via the MAPK signaling pathway. J Biol Chem. 2001; 276(37):34545-52. DOI: 10.1074/jbc.M100280200. View

10.

Tiikkainen M, Hakkinen A, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H . Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004; 53(8):2169-76. DOI: 10.2337/diabetes.53.8.2169. View

11.

Koshiba K, Nomura M, Nakaya Y, Ito S . Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest. 2006; 53(1-2):87-94. DOI: 10.2152/jmi.53.87. View

12.

Araki T, Emoto M, Konishi T, Ikuno Y, Lee E, Teramura M . Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism. 2009; 58(2):143-8. DOI: 10.1016/j.metabol.2008.09.006. View

13.

Kirsch D, Baumgarten M, Deufel T, Rinninger F, Kemmler W, Haring H . Catecholamine-induced insulin resistance of glucose transport in isolated rat adipocytes. Biochem J. 1983; 216(3):737-45. PMC: 1152569. DOI: 10.1042/bj2160737. View

14.

Phillips S, Kung J, Ciaraldi T, Choe C, Christiansen L, Mudaliar S . Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab. 2009; 297(3):E767-73. PMC: 2739702. DOI: 10.1152/ajpendo.00378.2009. View

15.

Shibata R, Sato K, Pimentel D, Takemura Y, Kihara S, Ohashi K . Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 2005; 11(10):1096-103. PMC: 2828682. DOI: 10.1038/nm1295. View

16.

Yu J, Javorschi S, Hevener A, Kruszynska Y, Norman R, Sinha M . The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002; 51(10):2968-74. DOI: 10.2337/diabetes.51.10.2968. View

17.

Chan G, Deckelbaum R, Bolivar I, Goltzman D, Karaplis A . PTHrP inhibits adipocyte differentiation by down-regulating PPAR gamma activity via a MAPK-dependent pathway. Endocrinology. 2001; 142(11):4900-9. DOI: 10.1210/endo.142.11.8515. View

18.

Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R . Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett. 2001; 507(2):142-6. DOI: 10.1016/s0014-5793(01)02960-x. View

19.

Wang Z, Schraw T, Kim J, Khan T, Rajala M, Follenzi A . Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention. Mol Cell Biol. 2007; 27(10):3716-31. PMC: 1899995. DOI: 10.1128/MCB.00931-06. View

20.

Haluzik M, Parizkova J, Haluzik M . Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res. 2004; 53(2):123-9. View